Is that type of infrastructure and support a critical part of nurturing new technologies?
ScienceA Genentech-led team used a combination of targeted sequencing and microarray analyses in non-Hodgkin’s lymphoma cell lines to find mutation and gene expression patterns linked to resistance or sensitivity to dacetuzumab, a CD40-stimulating antibody being investigated for the treatment of diffuse large B cell lymphomas and other B cell cancers. • BusinessQuest Diagnostics will buy Celera for $671 million, or $344 million net of cash and short-term investments. “For Quest Diagnostics, this is an important transaction which will further strengthen our leadership position in molecular diagnostics discovery and development and drive sustainable revenue growth,” Quest’s chairman and CEO said. • FundingThe National Institute of Allergy and Infectious Diseases plans to commit $20.2 million to fund development of medical diagnostics, therapeutics, vaccines, and other technologies for use as countermeasures for pathogens and toxins. NIAID plans to fund 15 to 20 grants to investigators th
